1681 Stock Overview
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Consun Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.41 |
| 52 Week High | HK$7.16 |
| 52 Week Low | HK$4.31 |
| Beta | 0.62 |
| 11 Month Change | -19.01% |
| 3 Month Change | -6.40% |
| 1 Year Change | 6.29% |
| 33 Year Change | 4.04% |
| 5 Year Change | 1.12% |
| Change since IPO | 10.41% |
Recent News & Updates
Recent updates
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
Jun 12
Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30
May 12Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30
Jun 01Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20
Apr 28Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20
Apr 07Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Aug 26Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?
Mar 17Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative
Feb 19How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 29Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?
Jan 08
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?
Nov 18Shareholder Returns
| 1681 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -2.5% | -4.1% | 0.6% |
| 1Y | 6.3% | -3.5% | 2.4% |
Return vs Industry: 1681 exceeded the Hong Kong Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: 1681 exceeded the Hong Kong Market which returned 2.4% over the past year.
Price Volatility
| 1681 volatility | |
|---|---|
| 1681 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1681's share price has been volatile over the past 3 months.
Volatility Over Time: 1681's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,127 | Meng An | www.chinaconsun.com |
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products.
Consun Pharmaceutical Group Limited Fundamentals Summary
| 1681 fundamental statistics | |
|---|---|
| Market cap | HK$4.50b |
| Earnings (TTM) | HK$843.32m |
| Revenue (TTM) | HK$2.78b |
5.3x
P/E Ratio1.6x
P/S RatioIs 1681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1681 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.59b |
| Cost of Revenue | CN¥668.44m |
| Gross Profit | CN¥1.92b |
| Other Expenses | CN¥1.14b |
| Earnings | CN¥784.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 74.19% |
| Net Profit Margin | 30.29% |
| Debt/Equity Ratio | 12.8% |
How did 1681 perform over the long term?
See historical performance and comparison